Medical - Diagnostics & Research
Compare Stocks
2 / 10Stock Comparison
CHEK vs ISRG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
CHEK vs ISRG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Instruments & Supplies |
| Market Cap | $12M | $160.44B |
| Revenue (TTM) | $0.00 | $10.58B |
| Net Income (TTM) | $-25M | $2.98B |
| Gross Margin | — | 66.3% |
| Operating Margin | — | 30.5% |
| Forward P/E | — | 43.7x |
| Total Debt | $136K | $303M |
| Cash & Equiv. | — | $3.37B |
CHEK vs ISRG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | Jan 26 | Return |
|---|---|---|---|
| Check-Cap Ltd. (CHEK) | 100 | 19.8 | -80.2% |
| Intuitive Surgical,… (ISRG) | 100 | 292.9 | +192.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CHEK vs ISRG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CHEK carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.67
- Lower volatility, beta 0.67, current ratio 0.15x
- Beta 0.67, current ratio 0.15x
ISRG is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 5.6% 10Y total return vs CHEK's -99.7%
- 20.5% revenue growth vs CHEK's -48.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs CHEK's -48.5% | |
| Quality / Margins | 212.2% margin vs ISRG's 28.2% | |
| Stability / Safety | Beta 0.67 vs ISRG's 1.02 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +101.9% vs ISRG's -14.8% | |
| Efficiency (ROA) | 14.8% ROA vs CHEK's -66.7%, ROIC 15.0% vs -287.7% |
CHEK vs ISRG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
CHEK vs ISRG — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ISRG and CHEK operate at a comparable scale, with $10.6B and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $0 | $10.6B |
| EBITDAEarnings before interest/tax | -$26M | $3.8B |
| Net IncomeAfter-tax profit | -$25M | $3.0B |
| Free Cash FlowCash after capex | -$8,004 | $2.8B |
| Gross MarginGross profit ÷ Revenue | — | +66.3% |
| Operating MarginEBIT ÷ Revenue | — | +30.5% |
| Net MarginNet income ÷ Revenue | — | +28.2% |
| FCF MarginFCF ÷ Revenue | — | +26.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +23.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -155.6% | +18.8% |
Valuation Metrics
CHEK leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $12M | $160.4B |
| Enterprise ValueMkt cap + debt − cash | $12M | $157.4B |
| Trailing P/EPrice ÷ TTM EPS | -0.48x | 57.40x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 43.67x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.64x |
| EV / EBITDAEnterprise value multiple | — | 43.44x |
| Price / SalesMarket cap ÷ Revenue | — | 15.94x |
| Price / BookPrice ÷ Book value/share | — | 9.13x |
| Price / FCFMarket cap ÷ FCF | — | 64.42x |
Profitability & Efficiency
ISRG leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-2 for CHEK. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs CHEK's 2/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -2.3% | +16.9% |
| ROA (TTM)Return on assets | -66.7% | +14.8% |
| ROICReturn on invested capital | -2.9% | +15.0% |
| ROCEReturn on capital employed | -2.3% | +16.5% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 |
| Debt / EquityFinancial leverage | — | 0.02x |
| Net DebtTotal debt minus cash | $136,000 | -$3.1B |
| Cash & Equiv.Liquid assets | — | $3.4B |
| Total DebtShort + long-term debt | $136,000 | $303M |
| Interest CoverageEBIT ÷ Interest expense | -2883.22x | — |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $16,086 today (with dividends reinvested), compared to $707 for CHEK. Over the past 12 months, CHEK leads with a +101.9% total return vs ISRG's -14.8%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.2% vs CHEK's 14.1% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +21.3% | -19.6% |
| 1-Year ReturnPast 12 months | +101.9% | -14.8% |
| 3-Year ReturnCumulative with dividends | +48.6% | +49.0% |
| 5-Year ReturnCumulative with dividends | -92.9% | +60.9% |
| 10-Year ReturnCumulative with dividends | -99.7% | +556.9% |
| CAGR (3Y)Annualised 3-year return | +14.1% | +14.2% |
Risk & Volatility
Evenly matched — CHEK and ISRG each lead in 1 of 2 comparable metrics.
Risk & Volatility
CHEK is the less volatile stock with a 0.67 beta — it tends to amplify market swings less than ISRG's 1.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ISRG currently trades 74.8% from its 52-week high vs CHEK's 53.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.67x | 1.02x |
| 52-Week HighHighest price in past year | $3.92 | $603.88 |
| 52-Week LowLowest price in past year | $0.59 | $427.84 |
| % of 52W HighCurrent price vs 52-week peak | +53.1% | +74.8% |
| RSI (14)Momentum oscillator 0–100 | 58.5 | 42.2 |
| Avg Volume (50D)Average daily shares traded | 2.5M | 1.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $622.60 |
| # AnalystsCovering analysts | — | 55 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.4% |
ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CHEK leads in 1 (Valuation Metrics). 1 tied.
CHEK vs ISRG: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CHEK or ISRG a better buy right now?
Intuitive Surgical, Inc.
(ISRG) offers the better valuation at 57. 4x trailing P/E (43. 7x forward), making it the more compelling value choice. Analysts rate Intuitive Surgical, Inc. (ISRG) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CHEK or ISRG?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +60. 9%, compared to -92. 9% for Check-Cap Ltd. (CHEK). Over 10 years, the gap is even starker: ISRG returned +556. 9% versus CHEK's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CHEK or ISRG?
By beta (market sensitivity over 5 years), Check-Cap Ltd.
(CHEK) is the lower-risk stock at 0. 67β versus Intuitive Surgical, Inc. 's 1. 02β — meaning ISRG is approximately 52% more volatile than CHEK relative to the S&P 500.
04Which is growing faster — CHEK or ISRG?
On earnings-per-share growth, the picture is similar: Intuitive Surgical, Inc.
grew EPS 22. 6% year-over-year, compared to -43. 3% for Check-Cap Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CHEK or ISRG?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus 0. 0% for Check-Cap Ltd. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus 0. 0% for CHEK. At the gross margin level — before operating expenses — ISRG leads at 66. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CHEK or ISRG?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CHEK or ISRG better for a retirement portfolio?
For long-horizon retirement investors, Intuitive Surgical, Inc.
(ISRG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02), +556. 9% 10Y return). Both have compounded well over 10 years (ISRG: +556. 9%, CHEK: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CHEK and ISRG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CHEK is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.